EP0222834A4 - Treatment of non-ulcer dyspepsia with bismuth salts. - Google Patents

Treatment of non-ulcer dyspepsia with bismuth salts.

Info

Publication number
EP0222834A4
EP0222834A4 EP19860903120 EP86903120A EP0222834A4 EP 0222834 A4 EP0222834 A4 EP 0222834A4 EP 19860903120 EP19860903120 EP 19860903120 EP 86903120 A EP86903120 A EP 86903120A EP 0222834 A4 EP0222834 A4 EP 0222834A4
Authority
EP
European Patent Office
Prior art keywords
treatment
bismuth salts
ulcer dyspepsia
dyspepsia
ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19860903120
Other languages
German (de)
French (fr)
Other versions
EP0222834A1 (en
Inventor
Thomas Julius Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3771057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0222834(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of EP0222834A1 publication Critical patent/EP0222834A1/en
Publication of EP0222834A4 publication Critical patent/EP0222834A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19860903120 1985-04-18 1986-04-18 Treatment of non-ulcer dyspepsia with bismuth salts. Ceased EP0222834A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU198/85 1985-04-18
AUPH019885 1985-04-18

Publications (2)

Publication Number Publication Date
EP0222834A1 EP0222834A1 (en) 1987-05-27
EP0222834A4 true EP0222834A4 (en) 1989-10-04

Family

ID=3771057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860903120 Ceased EP0222834A4 (en) 1985-04-18 1986-04-18 Treatment of non-ulcer dyspepsia with bismuth salts.

Country Status (5)

Country Link
EP (1) EP0222834A4 (en)
JP (1) JPS62502967A (en)
AU (1) AU590578B2 (en)
SG (1) SG72632A1 (en)
WO (1) WO1986005981A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318144T1 (en) * 1985-06-13 2006-03-15 Barry James Marshall PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL CONDITIONS, CONTAINING BISMUT AND AN ANTIMICROBIAL AGENT
ATE81011T1 (en) * 1987-03-09 1992-10-15 Procter & Gamble COMPOSITIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
AU623868B2 (en) * 1987-10-12 1992-05-28 Capability Services Pty. Limited Improved method for treatment of gastrointestinal disorders
JP2733849B2 (en) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス Improved method for treating gastrointestinal disorders
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
EP0375068A1 (en) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Combining bismuth compounds and tetracyclines
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
FI910088A (en) * 1990-01-09 1991-07-10 Gist Brocades Nv ORAL PHARMACEUTICAL COMPOSITION.
YU45590A (en) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. NEW COMPLEXES OR CHELATES OF ANTIBIOTICS WITH TWO-VALENT AND / OR TROVALENT METALS AND PROCEDURES FOR THEIR OBTAINING
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
EP0624373B1 (en) * 1993-05-11 1999-09-08 Spirig Ag Pharmazeutische Präparate Pharmaceutical preparation containing bismuth and amoxycillin and its use
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
PE48297A1 (en) * 1995-05-09 1998-02-04 Procter & Gamble METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
BR112013014827A2 (en) 2010-12-13 2016-10-04 Antony Wettstein gastric and colonic formulations and methods for producing and using the same
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6063965A (en) * 1965-06-25 1967-01-05 Morton W. Scott Belayed acting compositions
US3621094A (en) * 1968-04-05 1971-11-16 Smith Kline French Lab Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
GB1269987A (en) * 1968-04-18 1972-04-12 Garland Richard Brown Antacid composition
GB1220819A (en) * 1968-04-24 1971-01-27 Mar Pha Soc D Etude Et D Expl Improved bismuth salt
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
FR2029402A1 (en) * 1969-01-28 1970-10-23 Breive Et Son Jib Labo Regulation of digestion in gastro intestinal - passage
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
FR2073254A2 (en) * 1969-12-04 1971-10-01 Dausse Laboratoire Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders
AU440535B2 (en) * 1969-12-18 1973-09-17 Export Drugs Company Antacid compositions
FR2092636A1 (en) * 1970-06-03 1972-01-28 Griffon Henri Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders
ZA74385B (en) * 1974-01-18 1975-08-27 Gist Brocades Nv Pharmaceutical compositions
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
PH20649A (en) * 1981-09-22 1987-03-16 Gist Brocades Nv Bismuth containing composition and method for the preparation thereof
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
EP0206626B2 (en) * 1985-06-13 2002-05-22 Barry James Dr. Marshall Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis
ATE318144T1 (en) * 1985-06-13 2006-03-15 Barry James Marshall PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL CONDITIONS, CONTAINING BISMUT AND AN ANTIMICROBIAL AGENT

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 23, no. 5, May 1983, pages 796-797, American Society for Micrbiology; J. MICHEL et al.: "Susceptibility of clinical isolates of campylobacter jejuni to sixteen antimicrobial agents" *
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 28, no. 6, December 1985, pages 837-838, American Society for Microbiology; C.A.M. McNULTY et al.: "Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, page 161, abstract no. 097, Public Health Laboratory Service, London, GB; D.M. JONES et al.: "The effects of various anti-ulcer regimens and antibiotics on the presence of Campylobacter pyloridis and its antibody" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, page 162, abstract no. 098, Public Health Laboratory Service, London, GB; M.L. LANGENBERG et al.: "The pathogenic role of campylobacter pyloridis studied by attempts to eliminate these organisms" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, page 163, abstract no. 099, Public Health Laboratory Service, London, GB; C.A.M. McNULTY et al.: "A trial to compare treatment with pepto-bismol (bismuth subsalicylate), placebo and erythromycin for the eradication of campylobacter pyloridis in patients with gastritis" *
CAMPYLOBACTER III, PROCEEDINGS OF THE THIRD INTERNATIONAL WORKSHOP ON CAMPYLOBACTER INFECTION, Ottawa, 7th-10th July 1985, pages 165,166, abstract no. 100, Public Health Laboratory Service, London, GB; B.J. MARSHALL et al.: "The antibacterial action of bismuth: early results of antibacterial regimens in the treatment of duodenal ulcer" *
GASTROENTEROLOGY, vol. 88, no. 5, 1985, page 1462; J.R. LAMBERT et al.: "Campylobacter like organisms (CLO) - in vivo and in vitro susceptibility to antimicrobial and antiulcer therapy" *
IMMUNIT[T UND INFEKTION, vol. 14, no. 2, April 1986, pages 58-62; G. KASPER et al.: "Klinische Bedeutung, Epidemiologie und Laboratoriumsdiagnostik von Campylobacter pyloridis" *
J. CLIN. PATHOL., vol. 39, 1986, pages 353-365; C.S. GOODWIN et al.: "Campylobacter pyloridis, gastritis, and peptic ulceration" *
See also references of WO8605981A1 *
THE JOURNAL OF INFECTIOUS DISEASES, vol. 153, no. 4, April 1986, pages 650-657; B.J. MARSHALL: "Campylobacter pyloridis and gastritis" *
THE LANCET, 15th August 1987, page 398; B.J. RATHBONE et al.: "Campylobacter pylori and peptic ulcer" *
THE MEDICAL JOURNAL OF AUSTRALIA, vol. 142, 15th April 1985, pages 439-444; B.J. MARSHALL et al.: "Pyloric campylobacter infection and gastroduodenal disease" *

Also Published As

Publication number Publication date
AU5902686A (en) 1986-11-05
JPS62502967A (en) 1987-11-26
EP0222834A1 (en) 1987-05-27
SG72632A1 (en) 2000-05-23
WO1986005981A1 (en) 1986-10-23
AU590578B2 (en) 1989-11-09

Similar Documents

Publication Publication Date Title
EP0222834A4 (en) Treatment of non-ulcer dyspepsia with bismuth salts.
GB8526770D0 (en) Treating wafers with fluids
NO861972L (en) Vessel with multiple hulls.
GB8512533D0 (en) Treating wafers with fluids
EP0214818A3 (en) Active compounds
ZA86246B (en) Ribbon cassettes
AT383323B (en) BOAT DRIVE
GB2189239B (en) Furosemide salts
FI852606A0 (en) STOL MED ARMSTOED.
DK34585A (en) ANTIBACTERIAL NAPHTHYRIDINE AND PYRIDOPYRIMIDINE COMPOUNDS
PT82950A (en) Process for the preparation of antimicrobian isothiazolone solutions
GB8501406D0 (en) Ribbon cassettes
GB8507580D0 (en) Drive mechanisms
GB8603430D0 (en) Drive mechanisms
GB8512657D0 (en) Fishing tackel
GR861673B (en) Active chemical compounds preparation method
FI871049A0 (en) REGLERSYSTEM FOER PROPELLER MED REGLERBAR PROPELLERSTIGNING.
GB8606207D0 (en) Polyacrylamide solutions
DE3661882D1 (en) Regenerator plant
GB8601643D0 (en) Ribbon cassettes
GB8505065D0 (en) Sterilising solutions
HUT41586A (en) Fish-hook
ZA85403B (en) Naphthyridine and pyridopyrimidine antibacterial compounds
IE852413L (en) Thiazolidinediones.
GB8516549D0 (en) Complex salts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870422

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE PROCTER & GAMBLE COMPANY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BORODY, T. J.

A4 Supplementary search report drawn up and despatched

Effective date: 19891004

17Q First examination report despatched

Effective date: 19910723

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19981110

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE